Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin

Eric R. Henry, Belhu Metaferia, Quan Li, Julia Harper, Robert B. Best, Kristen E. Glass, Troy Cellmer, Emily B. Dunkelberger, Anna Conrey, Swee Lay Thein, H. Franklin Bunn, William A. Eaton

Blood (2021) 138 (13): 1172–1181.

https://doi.org/10.1182/blood.2021012070

Published: 2021

Includes: Supplemental data

Journal Articles

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Russell E. Ware, MD PhD, Clark Brown, MD PhD, Mariane de Montalembert, MD PhD, Margaret Tonda, PharmD, Barbara Tong, PhD, Carolyn Hoppe, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Miguel R. Abboud, MD

Blood (2019) 134 (Supplement_1): 1003.

https://doi.org/10.1182/blood-2019-130767

Published: 2019

Journal Articles

Education Program to Improve the Adherence to Guidelines for Use of Blood Transfusions in Sickle Cell Disease

Jennel Zeppieri, MD BSc, Dongyoun Deborah Park, MD BA, Kelley Mowatt, DO, Mohammed Sharif, MD, Alice J. Cohen, MD

Blood (2019) 134 (Supplement_1): 2115.

https://doi.org/10.1182/blood-2019-131766

Published: 2019

Journal Articles

Characterization of a Genetically Engineered HUDEP2 Cell Line Harboring a Sickle Cell Disease Mutation As a Potential Research Tool for Preclinical Sickle Cell Disease Drug Discovery

Dipti Gupta, Sarah Sturtevant, BSc, Benjamin Vieira, BS, Yukio Nakamura, MD PhD, Sriram Krishnamoorthy, PhD, Melanie Demers, PhD

Blood (2019) 134 (Supplement_1): 3559.

https://doi.org/10.1182/blood-2019-127330

Published: 2019

Journal Articles

Pharmacological Increase of Hb-O 2 Affinity with a Voxelotor Analog Does Not Decrease Brain Tissue pO 2 or Limit O 2 Extraction in Brain Tissues of Sickle Cell Mice

Kobina Dufu, PhD, Alfredo Lucas, MS, Cynthia Rodrigues Muller, PhD, Alexander T Williams, MS, Xinchun Zhang, MS, Peter Rademacher, PhD, Carsten Alt, MSc, PhD, Donna Oksenberg, PhD, Pedro Cabrales, PhD

Blood (2019) 134 (Supplement_1): 3564.

https://doi.org/10.1182/blood-2019-129282

Published: 2019

Journal Articles

MetAP2 Inhibition Modifies Hemoglobin S (HbS) to Delay Polymerization and Improve Blood Flow in Sickle Cell Disease

Melanie Demers, PhD, Sarah Sturtevant, BSc, Kevin Guertin, PhD, Dipti Gupta, Kunal Desai, MS, Benjamin Vieira, BS, Alexandra Hicks, PhD, Ayman Ismail, PhD, Yukio Nakamura, MD PhD, Bronner Goncalves, MD PhD, Giuseppe Di Caprio, PhD, Ethan Schonbrun, PhD, Scott Hansen, BS, Martin K. Safo, PhD, David K. Wood, PhD, John M. Higgins, MD PhD, David R. Light, PhD

Blood (2019) 134 (Supplement_1): 2260.

https://doi.org/10.1182/blood-2019-128727

Published: 2019

Journal Articles

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Satheesh Chonat, MD, Earl Fields, Hannah Baratz, Amanda Watt, Mira Pochron, PhD, Sandy Dixon, Margaret Tonda, PharmD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Clark Brown, MD PhD, David R. Archer, PhD

Blood (2019) 134 (Supplement_1): 2281.

https://doi.org/10.1182/blood-2019-129351

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

Differential Efficacy of Anti-Sickling and Anti-Inflammatory Mechanisms in a Fluorescent Intravital Microscopy Dorsal Skinfold Vaso-Occlusion Model in Sickle Cell Disease Townes Mice

Sarah Sturtevant, BSc, Alejandra Macias-Garcia, PhD, Sriram Krishnamoorthy, PhD, Arjan van der Flier, PhD, Alexandra Hicks, PhD, Melanie Demers, PhD

Blood (2019) 134 (Supplement_1): 2264.

https://doi.org/10.1182/blood-2019-128922

Published: 2019

Journal Articles

Effects of Voxelotor (GBT440) Therapy on Laboratory Testing of Sickle Cell Patients

Michelle E. Savedra, MT(ASCP), Jessica L. Szuberski, MLS ASCP, Tavanna R. Porter, MS, LCGC, Molly S. Hein, Phuong L. Nguyen, MD, Min Shi, MD PhD, Aruna Rangan, MD, James D. Hoyer, MD, Jennifer L. Oliveira, MD

Blood (2019) 134 (Supplement_1): 1011.

https://doi.org/10.1182/blood-2019-131125

Published: 2019

Journal Articles

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Jo Howard, MB, BChir, Elliott Vichinsky, MD UCSF, Jennifer Knight-Madden, MBBS, PhD, Margaret Tonda, PharmD, Carla Washington, Barbara Tong, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Victor R Gordeuk, MD

Blood (2019) 134 (Supplement_1): 1020.

https://doi.org/10.1182/blood-2019-130802

Published: 2019

Journal Articles

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Jo Howard, Claire Jane Hemmaway, Paul Telfer, D. Mark Layton, John Porter, Moji Awogbade, Timothy Mant, Daniel D. Gretler, Kobina Dufu, Athiwat Hutchaleelaha, Mira Patel, Vincent Siu, Sandra Dixon, Noel Landsman, Margaret Tonda, Joshua Lehrer-Graiwer

Blood (2019) 133 (17): 1865–1875.

https://doi.org/10.1182/blood-2018-08-868893

Published: 2019

Journal Articles

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Clark Brown, Carolyn Hoppe, Adlette Inati, Miguel R. Abboud, Winfred Wang, MD, Robert Liem, MD, Gerald Woods, Lewis L. Hsu, Victor R. Gordeuk, MD, Connie Piccone, Richard A. Drachtman, Erica Fong, Sandra Dixon, Margaret Tonda, PharmD, Carla Washington, Joshua Lehrer-Graiwer

Blood (2018) 132 (Supplement 1): 509.

https://doi.org/10.1182/blood-2018-99-117510

Published: 2018

Journal Articles

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Blood (2018) 132 (Supplement 1): 505.

https://doi.org/10.1182/blood-2018-99-118508

Published: 2018

Journal Articles

LC-MS Analysis of Anti-Sickling Compounds in Cord Blood Derived RBCs Demonstrates Modification of Fetal Hemoglobin and Globin Chain Binding Preferences

Benjamin Vieira, Vu P. Hong, Kunal Desai, Martin K. Safo, David R. Light

Blood (2018) 132 (Supplement 1): 1074.

https://doi.org/10.1182/blood-2018-99-116319

Published: 2018

Journal Articles

Sickle Human Umbilical Cord Derived Erythroid Progenitor Cells (S-HUDEP2): An Ideal in-Vitro System for Screening Anti-Sickling Compounds for Sickle Cell Disease

Alicia Chang, MD, So Hyun Park, BS, Ciaran M Lee, PhD, Alireza Paikari, MD, Gang Bao, PhD, Vivien A Sheehan, MD PhD

Blood (2018) 132 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2018-99-117158

Published: 2018

Journal Articles

A Single Center Experience of GBT440 Treatment of Severe Anemia in Sickle Cell Disease (SCD)

Kenneth R. Bridges, MD, Blyden Gershwin, MD, Lanetta Bronte

Blood (2017) 130 (Supplement 1): 3545.

https://doi.org/10.1182/blood.V130.Suppl_1.3545.3545

Published: 2017

Journal Articles

GBT1118 Diminishes Vaso-Occlusion in Sickle Cell Disease Mice

Carsten Alt, PhD, Perry Liu, Chien-Ming Li, PhD, Abel Silva, Peter Rademacher, PhD, Hilary Zou, Mira Patel, PhD, Kobina Dufu, PhD, Donna Oksenberg, PhD, Katalin Kauser, MD PhD

Blood (2017) 130 (Supplement 1): 3516.

https://doi.org/10.1182/blood.V130.Suppl_1.3516.3516

Published: 2017

Journal Articles

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Carla B Washington, PhD, Michelle Green, PhD, Adlette C. Inati, MD, Clark Brown, MD PhD, Carolyn C Hoppe, MD, Winfred Wang, MD, Ganesh Balaratnam, MD, Sandra Dixon, MS, Erica Fong, Athiwat Hutchaleelaha, PhD, Margaret E Tonda, PharmD, Josh Lehrer, MD MPhil, FACC

Blood (2017) 130 (Supplement 1): 980.

https://doi.org/10.1182/blood.V130.Suppl_1.980.980

Published: 2017

Journal Articles

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

Carolyn C Hoppe, MD, Adlette C. Inati, MD, Clark Brown, MD PhD, Winfred Wang, MD, Victor R. Gordeuk, MD, Robert Liem, MD, Gerald Woods, MD, Connie M. Piccone, MD, Erica Fong, Ganesh Balaratnam, MD, Sandy Dixon, Margaret E Tonda, PharmD, Carla B Washington, PhD, Yifah Yaron, MD PhD, Josh Lehrer, MD MPhil, FACC

Blood (2017) 130 (Supplement 1): 689.

https://doi.org/10.1182/blood.V130.Suppl_1.689.689

Published: 2017

NARROW

Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Education Program to Improve the Adherence to Guidelines for Use of Blood Transfusions in Sickle Cell Disease

Characterization of a Genetically Engineered HUDEP2 Cell Line Harboring a Sickle Cell Disease Mutation As a Potential Research Tool for Preclinical Sickle Cell Disease Drug Discovery

Pharmacological Increase of Hb-O 2 Affinity with a Voxelotor Analog Does Not Decrease Brain Tissue pO 2 or Limit O 2 Extraction in Brain Tissues of Sickle Cell Mice

MetAP2 Inhibition Modifies Hemoglobin S (HbS) to Delay Polymerization and Improve Blood Flow in Sickle Cell Disease

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Differential Efficacy of Anti-Sickling and Anti-Inflammatory Mechanisms in a Fluorescent Intravital Microscopy Dorsal Skinfold Vaso-Occlusion Model in Sickle Cell Disease Townes Mice

Effects of Voxelotor (GBT440) Therapy on Laboratory Testing of Sickle Cell Patients

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

LC-MS Analysis of Anti-Sickling Compounds in Cord Blood Derived RBCs Demonstrates Modification of Fetal Hemoglobin and Globin Chain Binding Preferences

Sickle Human Umbilical Cord Derived Erythroid Progenitor Cells (S-HUDEP2): An Ideal in-Vitro System for Screening Anti-Sickling Compounds for Sickle Cell Disease

A Single Center Experience of GBT440 Treatment of Severe Anemia in Sickle Cell Disease (SCD)

GBT1118 Diminishes Vaso-Occlusion in Sickle Cell Disease Mice

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only